Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific Antibodies

This competitive program supports independent quality improvement initiatives to optimize and standardize routine clinical practices for Multiple Myeloma patients receiving Bispecific Antibodies in Spain, focusing on improving health status and quality of life through enhanced healthcare delivery.

Overview

• Total available budget: approximately €130,000 [Page 1, Key Milestones section]
• Individual grant awards: up to €40,000 for large-reach, high-impact initiatives; smaller projects (~€20,000) encouraged [Page 1, Funding Range section]
• Project duration: maximum 18 months starting September 2026 [Page 1, Funding Range section]
• Award includes direct costs, institutional overhead (capped at 28% per Pfizer policy), and indirect costs [Page 3, Expected Approximate Monetary Range section]
• Geographic scope: Spain only [Page 1, Geographic Scope section]
• Independent review process through Pfizer's internal competitive grant program [Page 1, subtitle]
• Grantees maintain full responsibility for project design, implementation, and conduct; Pfizer not involved in project development or monitoring [Page 4, About Pfizer Grants section]

Priority Areas

• Care Integration & Coordination: "Improving integration, continuity, and communication of care delivery, including coordination across care settings, primary–specialty care integration, mentorship between centers, and effective teamwork to reduce variation in routine practice" [Page 1, Project Types section]
• Safety & Process Standardization: "Standardizing care processes to enhance safety and system performance, such as caregiver support, robust adverse event management and reporting, and the use of routinely collected data to identify and close performance gaps at local or national level" [Page 1, Project Types section]
• Technology & Tool Optimization: "Optimizing implementation of existing tools and technologies, including remote monitoring and established care pathways, to improve patient outcomes and support consistent, high-quality care" [Page 1, Project Types section]
• Continuity Across Settings: "Ensuring continuity of care across inpatient and outpatient settings" [Page 2, General Area of Interest section]
• Caregiver Support: Caregiver readiness and support programs [Page 2, General Area of Interest section]
• Data-Driven Improvement: Primary and specialty care integration programs, data-driven projects for systematic improvement at local or national level [Page 2, General Area of Interest section]
• Adverse Event Management: "Robust processes for adverse event (AE) management and reporting, including CRS, ICANS, and infections" [Page 2, General Area of Interest section]
• Mentorship Networks: Networks between academic and community centers for optimal patient selection and therapy management [Page 2, General Area of Interest section]
• Communication Strategies: Innovative communication strategies among care teams [Page 2, General Area of Interest section]
• Remote Monitoring: Technology solutions such as remote monitoring to improve patient outcomes [Page 2, General Area of Interest section]
• Equitable Access: "Approaches to guarantee equitable access to BsAb regardless of geography or socioeconomic status" [Page 2, General Area of Interest section]

Eligibility & Requirements

• Eligible Organizations: Healthcare institutions, professional associations, medical societies, patient advocacy groups (PAGs) involved in MM patient assistance located in Spain [Page 2, Applicant Eligibility Criteria section]
• Organization Requirement: Only organizations eligible; individuals or independent medical practice groups not eligible [Page 2, Applicant Eligibility Criteria section]
• Collaborations: Within institutions and between different institutions/organizations/associations encouraged; all partners must have relevant role and requesting organization must have key role [Page 2, Applicant Eligibility Criteria section]
• Applicant Role: Must be Project Lead/Principal Investigator or authorized designee (e.g., grant/research coordinator) [Page 2, Applicant Eligibility Criteria section]
• Employment Status: Project Lead/PI must be employee or contractor of requesting organization [Page 2, Applicant Eligibility Criteria section]
• Funding Capability: "Requesting organization must be legally able to receive award funding directly from Pfizer International LLC" - applicants strongly advised to confirm prior to submission [Page 2, Applicant Eligibility Criteria section]
• Primary Audience: Healthcare professionals focused on MM (hematologists, specialty nurses, psychologists, pharmacists) and/or MM patient advocacy organizations [Page 3, Target Audience section]
• Project Focus: Must be quality improvement initiatives, not clinical research; "Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered" [Page 2, General Area of Interest section]
• Core Requirement: Projects must apply existing evidence, standards, and best practices to improve patient care through "practical, locally adapted solutions" [Page 2, General Area of Interest section]
• Capital Restrictions: "Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable" [Page 7, Budget Detail section]
• Therapeutic Agent Restriction: "Grants awarded through ER&G cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription)" [Page 7, Budget Detail section]
• Overhead Cap: Maximum 28% institutional overhead rate [Page 7, Budget Detail section]

Timeline

• RFP Release: March 23, 2026 [Page 3, Key Dates section]
• Submission Deadline: May 8, 2026 (23:59 Eastern Standard Time) - "applications submitted after the due date will not be reviewed" [Page 3, Key Dates section]
• Award Notification: June 2026 [Page 1, Key Milestones section and Page 3, Key Dates section]
• Project Start: September 2026 [Page 1, Key Milestones section and Page 3, Key Dates section]
• Project End: March 2028 (maximum 18-month duration) [Page 3, Key Dates section]
• Grant Distribution: "Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver" [Page 3, Expected Approximate Monetary Range section]

How to Submit

• Access Portal: Go to www.cybergrants.com/pfizer/QI and sign in; first-time users click "Create your password" [Page 3, How to Submit section]
• Start Application: Click "Start A New Quality Improvement Grant Application" button [Page 3, How to Submit section]
• Complete Required Sections: Fill out all required sections of online application [Page 3, Requirements for submission section]
• Upload Proposal: Upload full proposal in the Proposal/Protocol field [Page 3, Requirements for submission section]
• Select Grant Type: For "Competitive Grant?" question, select "Yes" [Page 4, In the application section]
• Select Area: Choose Primary Area of Interest: "Oncology - Hematologic - QI" [Page 4, In the application section]
• Select Program: Choose Competitive Grant Program Name: "2026 ONC ES Optimal Clinical Care in Multiple Myeloma QI" [Page 4, In the application section]
• Proposal Format: Single-spaced, Calibri 12-point font, 1-inch margins, 15-page limit (exclusive of references) [Page 6, RFP Submission Requirements section]
• Required Proposal Sections: Goals and Objectives, Assessment of Need (with quantitative baseline data), Target Audience, Project Design and Methods, Innovation, Evaluation and Outcomes, Anticipated Project Timeline, Additional Information, Organization Detail, Budget Detail (in EUR) [Pages 6-7, Appendix section]
• Review Process: Grant requests reviewed by Pfizer to make final decisions; applicants may be asked for additional clarification during review [Page 4, Review and Approval Process section]
• Notification: All applicants notified via email by dates noted [Page 4, Mechanism by which Applicants will be Notified section]
• Grant Agreement: If approved, written grant agreement required; modifications only reviewed if genuine conflict exists between applicable law and agreement terms [Page 4, Grant Agreements section]
• Technical Questions: Click "Technical Questions" link in cybergrants portal [Page 4, Questions section]
• Program Questions: Contact Grant Officer Nicola Fenderico (Nicola.Fenderico@Pfizer.com) with subject line "2026 ONC ES Optimal Clinical Care in Multiple Myeloma QI" [Page 4, Questions section]

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.